Bellevue Life Sciences 8-K: Material Agreements & Officer Changes

TL;DR

Bellevue Life Sciences 8-K filed: Material agreements and exec changes reported.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed an 8-K on May 30, 2024, reporting on material definitive agreements and changes in directors/officers as of May 23, 2024. The filing details the company's structure, including units consisting of common stock, redeemable warrants, and rights, and its standard industrial classification in Surgical & Medical Instruments & Apparatus.

Why It Matters

This filing provides crucial updates on the company's corporate structure and potential material agreements, which could impact its strategic direction and investor outlook.

Risk Assessment

Risk Level: low — This is a routine 8-K filing detailing corporate structure and standard reporting items, not indicating immediate significant financial risk.

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer
• May 23, 2024 (date) — Earliest event reported
• May 30, 2024 (date) — Date of report
• 3841 (other) — Standard Industrial Classification Code

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $250,339,610 — the Aggregate Consideration Value from $250,339,610 to $244,612,136; and (iv) changes to th
• $244,612,136 — onsideration Value from $250,339,610 to $244,612,136; and (iv) changes to the designation of

Filing Documents

• d843259d8k.htm (8-K) — 50KB
• d843259dex21.htm (EX-2.1) — 420KB
• 0001193125-24-150364.txt ( ) — 756KB
• blacu-20240523.xsd (EX-101.SCH) — 5KB
• blacu-20240523_def.xml (EX-101.DEF) — 15KB
• blacu-20240523_lab.xml (EX-101.LAB) — 26KB
• blacu-20240523_pre.xml (EX-101.PRE) — 16KB
• d843259d8k_htm.xml (XML) — 9KB

Forward-Looking Statements

Forward-Looking Statements This Current Report on Form 8-K includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of the businesses of BLAC and the Company may differ from their actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the satisfaction of the closing conditions to the proposed business combination, the timing of the completion of the proposed business combination and the future performance of the Company, including the anticipated impact of the proposed business combination on this performance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of BLAC and the Company and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreement with respect to the proposed business combination, (2) the outcome of any legal proceedings that may be instituted against the parties in connection with the proposed business combination; (3) the inability to complete the proposed business combination, including due to failure to obtain approval of the stockholders of BLAC or the failure of any other conditions to closing; (4) the impact of the COVID-19 pandemic (or any other global health disruption) on (x) the parties' ability

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 2.1* Amended and Restated Business Combination Agreement, dated as of May 23, 2024, between Bellevue Life Sciences Acquisition Corp. and OSR Holdings Co., Ltd. 10.1 Form of Participating Stockholder Joinder Agreement (Incorporated by reference to Exhibit 10.1 to BLAC's Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 16, 2023) 10.2 Form of Non-Participating Stockholder Joinder Agreement (Incorporated by reference to Exhibit 10.2 to BLAC's Current Report on Form 8-K (File No. 001-41390) filed with the SEC on November 16, 2023) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * Certain schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the SEC upon request. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: May 30, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR